Future of Novel Next-Generation Therapy in the Management of Relapsed/Refractory Multiple Myeloma

Watch a 24-minute medical lecture where Dr. Paul Richardson from Dana-Farber Cancer Institute explores the evolving landscape of multiple myeloma treatment, focusing on next-generation therapies for relapsed and refractory cases. Gain valuable insights into cutting-edge treatment approaches and emerging therapeutic options that are shaping the future of multiple myeloma care. Understand the clinical perspective on promising developments in managing this complex hematologic malignancy from one of the leading experts in the field at Dana-Farber's renowned Multiple Myeloma Program.